361-09-1

• 常用中文名：胆酸钠
• 常用英文名：sodium cholate
• CAS号：361-09-1
• 分子式：C₂₄H₄₀NaO₅
• 分子量：430.553
• 相关类别： 有机原料 有机金属盐
• 发布时间：2018-02-04 08:00:00
• 更新时间：2026-07-01 09:33:14
• 
  【用途一】
  防止胆石生成。
  
  【用途二】
  
  用于消炎。 

名称

• 中文名: 胆酸钠
• 英文名: sodium cholate
• 中文别名: 胆酸钠,从牛胆中所得; 胆固钠; SODIUM CHOLATE FROM BOVINE BILE[FOR BIOCHEMICAL ] 胆酸钠,从牛胆中所得; 胆汁酸 胆酸钠; 胆酸钠/Sodium cholate; 胆酸钠作用; 胆酸钠,来源于牛或羊胆汁; 【直销没有贸易赚钱中间价】胆酸钠-1/ 然提取物医药; 牛胆汁胆酸钠; 胆酸钠(猪)(饲料用); 胆酸钠,由牛胆汁中提取; 胆酸钠(牛); 食品级胆酸钠作用; 3α,7α,12α-三羟基-5β-胆烷酸; (3α,5β,7α,12α)-3,7,12-三羟基胆(甾)烷-24-酸单钠盐; L3ALPHA,7APHA,12ALPHA-三羟基-5BETA-胆烷酸钠; 胆酸钠原料药; 【供应】胆酸钠41945-含量,滴定法检测; 胆酸钠, 试剂; 胆酸钠盐; 胆酸钠报价; 胆汁酸盐; (R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-三羟基-10,13-二甲基十六氢-1H-环戊烷并[A]菲-17-基)戊酸钠盐; 3,7,12-三羟甾代异戊酸; 罗恩 胆酸钠 R097474-g; 胆酸钠(牛源); 3Α,7Α,12Α-三羟基-5Β-胆烷酸单钠盐; 罗恩 胆酸钠 R097473-g; 【纯天然供应】胆酸钠-1/ 然提取物医药; 牛羊胆酸; 食品级胆酸钠; 胆汁酸; 天然提取物胆酸钠; 胆酸钠标准品; 【纯天然】直销胆酸钠-1/ 然提取物医药; 胆酸钠,来源于牛或羊的胆汁; 胆汁钠; 胆酸纳; 胆酸钠-1/ 然提取物医药; 胆酸钠,水合物,来源于牛或羊的胆汁; 无水胆酸钠(猪); 食品级胆酸钠报价; 3α,7α,12α-三羟基-5β-胆烷酸单钠盐; 胆酸钠(-1)治疗胆囊炎】; 胆酸钠 (胆汁酸、胆酸钠盐、无合胆酸钠、(3Α,5Β, 7Α,12Α)-3,7,12-三羟基胆(甾)烷-24-酸单钠盐)
• 英文别名: colalin; cholic acid sodium; 5-BETA-CHOLANIC ACID-3-ALPHA, 7-ALPHA, 12-ALPHA-TRIOL SODIUM SALT; Cholan-24-oic acid, 3,7,12-trihydroxy-, monosodium salt, (3.alpha.,5.beta.,7.alpha.,12.alpha.); cholsaeure; 3,7,12-trihydroxy-cholan-24-oicacid(3-alpha,5-beta,7-alpha,12-alpha); SODIUM 3-ALPHA,7-ALPHA,12-ALPHA-TRIHYDROXY-5-BETA-CHOLAN-24-OATE; Cholic acid; CHOLALIC ACID; (4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate; Sodium Cholate from Bovine Bile [for Biochemical ]; SodiumCholate; 3ALPHA,7ALPHA,12ALPHA-TRIHYDROXY-5BETA-CHOLANIC ACID SODIUM SALT; CHOLIC ACID NA-SALT; SODIUMCHOLATE,REAGENT; Sodium cholate; 3α,7α,12α-Trihydroxy-5β-cholanic acid sodiuM salt; 3,7,12-Trihydroxy-5-chloanicacid; fromOXorshebile; Sodium; 3,7,12-trihydroxy-,(3-alpha,5-beta,7-alpha,12-alpha)-cholan-24-oicaci; 3-alpha,7-alpha,12-alpha-trihydroxycholansaeure; Natriumcholat; deoxycholic acid sodium salt; 5BETA-CHOLANIC ACID-3ALPHA,7ALPHA,12ALPHA-TRIOL SODIUM; Sodium cholate, from OX or shebile; Cattle&Shechdic acid; nsc-6135; Bile acide; SODIUM CHOLATE; 3ALPHA,7ALPHA,12ALPHA-TRIHYDROXYCHOLAN-24-OIC ACID SODIUM SALT; SodiumCholate(Purified); sodium salt of cholic acid; SODIUM, (R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-TRIHYDROXY-10,13-DIMETHYL-HEXADECAHYDRO-CYCLOPENTA[A]PHENANTHREN-17-YL)-PENTANOATE; Sodium Cholate BioChemica; Cholic acid,sodium salt; 3-ALPHA,7-ALPHA,12-ALPHA-TRIHYDROXY-5-BETA-CHOLAN-24-OIC ACID; Sodium Cholate from Bovine Bile; (4 R)-4-[(8 R,9 S,10 S,13 R,14 S,17 R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1 H-cyclopenta[a]phenanthren-17-yl]pentanoate; 3ALPHA,7ALPHA,12ALPHA-TRIHYDROXY-5ALPHA-CHOLAN-24-IC ACID; MFCD00064138; 17-beta-(1-methyl-3-cboxypropyl)etioc; SODIUMCHOLATE; Sodium Cholate >; 17-beta-(1-methyl-3-cboxypropyl)etiocholane-3alpha,7alpha,12alpha-triol; Sodium (3a,5b,7a,12a)-3,7,12-trihydroxycholan-24-oate; (R)-4-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-Trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid, sodium salt; Cholic acid, sodiuM salt, R; SodiumCholateForBiochemistry; D-GLUCOSE ANHYDROUS BIOTECHNOLOGY ADE; EINECS 206-643-5; SODIUM CHOLATE BOR BIOCHEMISTRY; 7,12-Triol; 3,7,12-trihydroxy-,(3alpha,5beta,7alpha,12alpha)-cholan-24-oicaci; SodiumCholatefromBovineBile[forBiochemicaesech]>; 3α,7α,12α-Trihydroxy-5β-cholan-24-oic acid sodium salt,Cholalic acid sodium salt; Sodium choL; Cholic acid, sodium salt; 17-(1-Methyl-3-cboxypropyl)etiocholane-3; SODIUM CHOLEATE; CHOLIC ACID SODIUM SALT

物化性质

• 沸点: 583.9ºC at 760 mmHg
• 熔点: 198ºC
• 分子式: C₂₄H₄₀NaO₅
• 分子量: 430.553
• 闪点: 321ºC
• 精确质量: 430.269531
• PSA: 100.82000
• LogP: 2.11400
• 外观性状: 白色晶体
• 折射率: 35 ° (C=0.6, EtOH)
• 储存条件:

  棕色玻璃瓶密封包装。低温下存放。

• 稳定性:

  1.胆酸一水合物为白色片状结晶。无水物熔点198℃。15℃溶解度（g/L）：水0.28；醇30.56；醚1.22；氯仿5.08；苯0.36；丙酮28.24；冰醋酸152.12，也溶于碱溶液。味先苦后甜，遇毛地黄皂苷不产生沉淀。

• 水溶解性: 150 g/L (20 ºC)
• 更多:

  性状：本品为白色粉末，无臭，味苦。

  密度（g/mL,25/4℃）：不可用

  相对蒸汽密度（g/mL,空气=1）：不可用

  熔点（ºC）：197-202

  沸点（ºC,常压）：不可用

  沸点（ºC,5.2kPa）：不可用

  折射率：不可用

  闪点（ºC）：不可用

  比旋光度（º）：不可用

  自燃点或引燃温度（ºC）：不可用

  蒸气压（kPa,25ºC）：不可用

  饱和蒸气压（kPa,60ºC）：不可用

  燃烧热（KJ/mol）：不可用

  临界温度（ºC）：不可用

  临界压力（KPa）：不可用

  油水（辛醇/水）分配系数的对数值：不可用

  爆炸上限（%,V/V）：不可用

  爆炸下限（%,V/V）：不可用

  溶解性：其碱金属盐均易溶于水和醇中。

生物活性

• 描述: Cholic acid sodium 是肝脏中产生的主要胆汁酸,通常与甘氨酸或牛磺酸缀合,有助于脂肪吸收和胆固醇排泄。
• 相关类别:
  研究领域 >> 代谢疾病
• 体外研究: 胆酸竞争性地结合HepG2细胞上的Na + /牛磺胆酸盐共转运多肽(NTCP),并显着抑制胆酸(CA)-纳米脂质体(LPs)-多柔比星(DOX)-HCl的摄取,这表明CA-LPs-DOX-HCl也通过NTCP介导的内吞途径摄取[1]。
• 细胞实验: 用抑制剂NaN3（1mg/mL）、染料木黄酮（50μg/mL）、MβCD（10mM）、制霉菌素（50μg/mL）、氯丙嗪（10μg/mL）和胆酸（1mg/mL）预处理HepG2细胞30分钟，除去抑制剂后，与CA-LPs孵育2小时，LPs的细胞摄取在“体外细胞摄取测定”部分[1]中确定。
• 参考文献:

  [1]. Li Y, et al. Mechanism of hepatic targeting via oral administration of DSPE-PEG-Cholic acid-modified nanoliposomes. Int J Nanomedicine. 2017 Feb 28;12:1673-1684.

  [2]. Pan X, et al. Cholic acid Feeding Leads to Increased CYP2D6 Expression in CYP2D6-Humanized Mice. Drug Metab Dispos. 2017 Apr;45(4):346-352.

MSDS

Name: Cholic acid sodium salt 99% (Titr.) Material Safety Data Sheet Synonym: Sodium cholate; 3alpha,7alpha,12alpha-Trihydroxy-5-cholanic acid sodium salt; Cholic acid, monosodium salt, sodium cholic acid; Cholan-24-oic acid, 3,7,12-trihydroxy-, monosodium salt, (3-alpha,5-beta,7-alpha; Cholic acid, monosodium salt; D CAS: 361-09-1 Section 1 - Chemical Product MSDS Name:Cholic acid sodium salt 99% (Titr.) Material Safety Data Sheet Synonym:Sodium cholate; 3alpha,7alpha,12alpha-Trihydroxy-5-cholanic acid sodium salt; Cholic acid, monosodium salt, sodium cholic acid; Cholan-24-oic acid, 3,7,12-trihydroxy-, monosodium salt, (3-alpha,5-beta,7-alpha; Cholic acid, monosodium salt; D Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS CAS# Chemical Name content EINECS# 361-09-1 Cholic acid sodium salt 99 206-643-5 Hazard Symbols: None Listed. Risk Phrases: None Listed. Section 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Hygroscopic (absorbs moisture from the air).The toxicological properties of this material have not been fully investigated. Potential Health Effects Eye: May cause eye irritation. Skin: May cause skin irritation. Ingestion: May cause irritation of the digestive tract. Inhalation: May cause respiratory tract irritation. May cause effects similar to those described for ingestion. Chronic: No information found. Section 4 - FIRST AID MEASURES Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately. Skin: Get medical aid. Get medical aid immediately. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse. Ingestion: Never give anything by mouth to an unconscious person. Get medical aid immediately. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Inhalation: Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Notes to Physician: Section 5 - FIRE FIGHTING MEASURES General Information: As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Extinguishing Media: Use water spray, dry chemical, carbon dioxide, or appropriate foam. Section 6 - ACCIDENTAL RELEASE MEASURES General Information: Use proper personal protective equipment as indicated in Section 8. Spills/Leaks: Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation. Section 7 - HANDLING and STORAGE Handling: Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Storage: Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Store protected from moisture. Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION Engineering Controls: Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 361-09-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. Skin: Wear appropriate protective gloves to prevent skin exposure. Clothing: Wear appropriate protective clothing to prevent skin exposure. Respirators: A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use. Section 9 - PHYSICAL AND CHEMICAL PROPERTIES Physical State: Crystals Color: white Odor: none reported pH: Not available. Vapor Pressure: Not available. Viscosity: Not available. Boiling Point: Not available. Freezing/Melting Point: 198 deg C Autoignition Temperature: Not applicable. Flash Point: Not applicable. Explosion Limits, lower: Not available. Explosion Limits, upper: Not available. Decomposition Temperature: Not available. Solubility in water: Soluble. Specific Gravity/Density: Not available. Molecular Formula: C24H39NaO5 Molecular Weight: 430.55 Section 10 - STABILITY AND REACTIVITY Chemical Stability: Stable under normal temperatures and pressures. Conditions to Avoid: Incompatible materials, strong oxidants, exposure to moist air or water. Incompatibilities with Other Materials: Oxidizing agents, moisture. Hazardous Decomposition Products: Acrid smoke and fumes. Hazardous Polymerization: Has not been reported. Section 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 361-09-1: FZ9600000 LD50/LC50: CAS# 361-09-1: Oral, mouse: LD50 = 2400 mg/kg. Carcinogenicity: Cholic acid sodium salt - Not listed by ACGIH, IARC, or NTP. Other: See actual entry in RTECS for complete information. Section 12 - ECOLOGICAL INFORMATION Section 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations. Section 14 - TRANSPORT INFORMATION IATA Not regulated as a hazardous material. IMO Not regulated as a hazardous material. RID/ADR Not regulated as a hazardous material. Section 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives Hazard Symbols: Not available. Risk Phrases: Safety Phrases: S 24/25 Avoid contact with skin and eyes. S 28A After contact with skin, wash immediately with plenty of water. S 37 Wear suitable gloves. S 45 In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). WGK (Water Danger/Protection) CAS# 361-09-1: 1 Canada CAS# 361-09-1 is listed on Canada's DSL List. CAS# 361-09-1 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 361-09-1 is listed on the TSCA inventory. SECTION 16 - ADDITIONAL INFORMATION N/A

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : FZ9600000 CHEMICAL NAME : Cholic acid, sodium salt CAS REGISTRY NUMBER : 361-09-1 LAST UPDATED : 199701 DATA ITEMS CITED : 7 MOLECULAR FORMULA : C24-H39-O5.Na MOLECULAR WEIGHT : 430.62 WISWESSER LINE NOTATION : L E5 B666TJ A1 DQ E1 FY1&2VO KQ OQ &-NA- &38/28 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 2400 mg/kg TOXIC EFFECTS : Behavioral - somnolence (general depressed activity) Gastrointestinal - ulceration or bleeding from stomach Gastrointestinal - ulceration or bleeding from small intestine REFERENCE : ESKHA5 Eisei Shikenjo Hokoku. Bulletin of the Institute of Hygienic Sciences. (Kokuritsu Eisei Shikenjo Kagaku, 18-1 Bushitsu Johobu, Setagaya-ku, Tokyo 158, Japan) V.1- 1886- Volume(issue)/page/year: (103),29,1985 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 164 mg/kg TOXIC EFFECTS : Behavioral - excitement Lungs, Thorax, or Respiration - other changes Gastrointestinal - hypermotility, diarrhea REFERENCE : ESKHA5 Eisei Shikenjo Hokoku. Bulletin of the Institute of Hygienic Sciences. (Kokuritsu Eisei Shikenjo Kagaku, 18-1 Bushitsu Johobu, Setagaya-ku, Tokyo 158, Japan) V.1- 1886- Volume(issue)/page/year: (103),29,1985 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 200 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 90,18,1952 TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : 50 mg/kg TOXIC EFFECTS : Behavioral - convulsions or effect on seizure threshold REFERENCE : ZGEMAZ Zeitschrift fuer die Gesamte Experimentelle Medizin. (Berlin, Fed. Rep. Ger.) V.1-139, 1913-65. For publisher information, see REXMAS. Volume(issue)/page/year: 52,779,1926 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - M1798 No. of Facilities: 82 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 82 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - M1798 No. of Facilities: 585 (estimated) No. of Industries: 2 No. of Occupations: 6 No. of Employees: 6463 (estimated) No. of Female Employees: 4599 (estimated)

安全

• 危害码 (欧洲): Xi
• 风险声明 (欧洲): 36/37/38
• 安全声明 (欧洲): S24/25
• RTECS号: FZ9600000

上下游产品

上游产品  1
81-25-4
下游产品  1
81-23-2

制备

1.将猪（或羊、牛）胆汁加热浓缩至半，趁热加入1～2倍体积的95%乙醇，回流提取，得提取液。提取液冷却，过滤，滤液浓缩后得浸膏。浸膏中加入稀盐酸，调节pH=3～4，放置过夜，倾出上清液，过滤，沉淀物为胆汁酸粗品。也可以将胆汁中加入氢氧化钠，加热煮沸20～24h，然后调整pH值为2～3，出现黑色膏状物，取出膏状物洗至中性，得粗胆汁酸。

粗胆汁酸加酸水洗1～2次，再加95%乙醇加热溶解，用碱调pH =8～8.5，然后加活性炭脱色，过滤，滤液蒸馏回收乙醇，然后结晶，过滤，干燥，可制得胆汁酸成品。